Business Context and Reporting Period
Company: Excaliber Enterprises, Ltd. (filing entity) / VistaGen Therapeutics, Inc. (operating entity)
Date: May 11, 2011
Event: Completion of a reverse merger. Excaliber Enterprises, Ltd. merged with VistaGen Therapeutics, Inc. via a wholly-owned subsidiary. VistaGen remains the surviving corporation and will operate as a wholly-owned subsidiary of Excaliber. The company intends to change its name to "VistaGen Therapeutics, Inc."
Business Model: VistaGen is a biotechnology company utilizing human pluripotent stem cell technology for "drug rescue" (modifying failed drug candidates to reduce toxicity) and cell therapy. Key assets include the "Human Clinical Trials in a Test Tube" platform, CardioSafe 3D (cardiac toxicity screening), and the drug candidate AV-101 (neuropathic pain).
Key Financial Metrics
Note: Financial data reflects VistaGen's operations as of December 31, 2010 (unaudited) and the fiscal year ended March 31, 2010 (audited).
| Metric | 9 Months Ended Dec 31, 2010 | Fiscal Year Ended Mar 31, 2010 |
|---|---|---|
| Total Revenues | $1.72 million | $2.21 million |
| Net Loss | $(5.95) million | $(4.12) million |
| Cash and Equivalents | $279,000 | $201,000 |
| Total Liabilities | $15.91 million | $13.02 million |
| Shareholders' Deficit | $(29.75) million | $(26.34) million |
| Accumulated Deficit | $(39.04) million | $(33.09) million |
Debt & Liquidity: The company has significant debt obligations, including convertible promissory notes (Platinum Notes, 2006/2007 Notes, 2008/2010 Notes) totaling approximately $14.3 million in principal. Management stated that cash on hand ($279,000) is insufficient to fund operations for the next 12 months, which are estimated to require approximately $6 million.
Material Changes and Transactions
- Merger Consideration: VistaGen shareholders received 6,836,511 shares of Excaliber common stock (approx. 90% of outstanding shares) at a ratio of 0.5 Excaliber shares for 1 VistaGen share.
- Private Placement: Immediately prior to the merger, VistaGen completed a private placement of 1,108,056 Units at $3.50 per unit, raising approximately $3.88 million. Each unit consisted of one share and a warrant to purchase 0.25 shares at $5.00.
- Debt Conversion: The proceeds from the private placement were deemed sufficient to trigger the automatic conversion of the "Amended and Restated Platinum Note" (approx. $4.63 million principal + interest) into equity securities.
- Related Party Transactions: Excaliber purchased 4,982,103 shares from Stephanie Y. Jones and 82,104 shares from Nicole Jones for a total of $10.00 each to facilitate the merger structure.
- Management Changes: Stephanie Y. Jones and Matthew L. Jones resigned as directors. H. Ralph Snodgrass, Gregory A. Bonfiglio, and Brian J. Underdown were appointed to the board. Shawn K. Singh became CEO.
Guidance, Outlook, and Risks
Outlook: Management anticipates completing Phase I clinical development of AV-101 in 2011. The company plans to leverage CardioSafe 3D to generate a pipeline of drug rescue variants and expects to produce stem cell-derived human liver cells within 12 months.
Risks and Contingencies:
- Going Concern: Independent auditors have expressed substantial doubt about the company's ability to continue as a going concern due to recurring losses and negative cash flows. Additional financing is required to avoid discontinuing operations.
- Technology Validation: The internal validation study for CardioSafe 3D has not been subject to peer review or third-party validation.
- Capital Needs: The company has no committed sources of additional capital. Failure to secure funding may result in dilution, asset sales, or cessation of operations.
- Regulatory: Success depends on FDA approval for AV-101 and acceptance of stem cell technologies by the pharmaceutical industry.
Investor Verification Checklist
- Capital Sufficiency: Verify the status of the $6 million funding requirement for the next 12 months and the terms of any new financing.
- Debt Conversion: Confirm the final share count and dilution impact resulting from the conversion of the Platinum Notes and other convertible debt triggered by the private placement.
- AV-101 Progress: Monitor the timeline and results of the Phase I clinical trials for AV-101, which is a primary revenue driver expectation.
- Grant Funding: Assess the reliability of future government grants (NIH, CIRM) which have historically funded a significant portion of operations.
- Stock Liquidity: Note that the stock trades on the OTC Bulletin Board and may have limited liquidity and high volatility.